Novel approach treatment of scleroderma lung disease with anti-LFA3 therapy

This pilot trial shows the feasibility of depleting T cells from scleroderma patients, including both the blood and lungs, Alefacept was well tolerated, and T cell depletion was associated with stability in lAuAng funtion over the period of the protocol. The data suggest that, at least in part, T cells may drive the non-specific inflammatory response in the lungs of these patients (AU)